GasLog Partners Azioni (NYSE: GLOPpC) prezzo delle azioni, notizie, grafici, ricerca sulle azioni, profilo.

GasLog Partners (NYSE:GLOPpC) Azioni Citazioni e riassunti delle notizie

GasLog Partners

GasLog Partners LP is a limited partnership that is predominantly engaged in the ownership, operation, and acquisition of LNG (liquefied natural gas), carriers engaged in LNG transportation under long-term charters. The company's fleet consists of nearly ten LNG carriers, including nine vessels with modern TFDE propulsion technology and three Steam vessels. GasLog operates its business through a single segment.

GasLog Partners LP 8.500% Series C Cumulative Redeemable Perpetual Fixed to Floating Rate Preference Units

GasLog Partners LP

WIIM

RGLD

Royal Gold shares are trading higher after the company reported better-than-expected Q4 financial results.

BMO Capital analyst Kelly Bania maintains Chefs' Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) with a Outperform and raises the price target from $60 to $73.

News

Price Target

Analyst Ratings

CHEF

BMO Capital Maintains Outperform on Chefs' Warehouse, Raises Price Target to $73

Rosenblatt analyst Mike Genovese upgrades Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Neutral to Buy and raises the price target from $66 to $80.

Upgrades

CSCO

Rosenblatt Upgrades Cisco Systems to Buy, Raises Price Target to $80

QDEL

QuidelOrtho shares are trading higher after the company reported better-than-expected Q4 financial results. Also, UBS maintained a Neutral rating ont he stock and raised its price target from $43 to $45.

On Thursday,&nbsp;West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) reported a fourth-quarter adjusted EPS of $1.82, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.72</a>.
The designer and manufacturer of injectable pharmaceutical packaging and delivery systems reported sales of $748.8 million, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43687013/west-announces-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">consensus of $740.47 million</a>.
The Proprietary Products Segment's sales increased by 3.4% to $613.9 million, and the organic net sales growth was 4.5%.
High-value products (components and devices) represented around 74% of segment net sales, led by customer demand for self-injection device platforms. Fourth-quarter sales included a benefit of approximately $25&nbsp;million in customer incentives earned in connection with volumes achieved related to HVP Delivery Devices.
The Biologics market unit experienced high-single-digit organic net sales growth, driven by an increase in sales of self-injection device platforms, offset by lower sales of NovaPure products.
The Pharma market unit saw mid-single-digit organic net sales growth, driven by an increase in Westar products and Administrative Systems sales.
The Generics market unit had a mid-single digit organic net sales decline, driven by lower volumes of FluroTec products.
Sales in the Contract-Manufactured Products Segment declined by 2.5% to $134.9 million, while organic net sales declined by 2.0%. Segment performance was driven by a continued decrease in sales of healthcare diagnostic devices, partially offset by growth in self-injection devices for obesity and diabetes.
Guidance: West Pharmaceutical Services forecasts 2025 adjusted EPS of $6.00-$6.20 below the consensus of $7.44.
The company expects 2025 revenues of $2.875 billion-$2.91 billion versus a consensus of $3.04 billion.
<ul>
<li>Organic net sales growth is expected to be approximately 2% to 3%.</li>
<li>Net sales guidance includes an estimated full-year 2025 headwind of $75 million based on current foreign currency exchange rates.</li>
</ul>
"Looking ahead to 2025, we expect our business momentum to continue in key areas of our Proprietary Products business, driven by improving High-Value Products trends in Biologics and Generics, and growth driven by Annex 1 and GLP-1. We are focused on operational excellence and driving strong returns in 2025," said Eric Green, President, Chief Executive Officer and Chair.
William Blair writes that West Pharmaceutical stock currently trades at 52.8 times the midpoint of the company's 2025 adjusted EPS guidance.
"Generally speaking, we expect the stock to track to earnings growth that we peg in the low- to midteens long term; however, we believe both 1) that growth profile may not return until mid-to late 2025 and 2) much of the alpha will be recaptured moving into that return-to growth," writes analyst Matt Larew.
William Blair reiterates <a target="_blank" href="https://www.benzinga.com/quote/WST/analyst-ratings" rel="noreferrer noopener">the Outperform rating</a>.
Price Action:&nbsp;On Thursday&#8217;s last check, WST stock was down 33.90% at $213.25.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43694603/hertz-misses-on-revenue-profit-as-fleet-shrinks-costs-weigh" target="_blank" rel="noreferrer noopener">Hertz Misses On Revenue, Profit As Fleet Shrinks, Costs Weigh</a></li>
</ul>

Analyst Color

Earnings

Large Cap

Guidance

Health Care

Movers

Trading Ideas

General

West Pharmaceutical Stock Sinks On Weaker Than Expected 2025 Guidance

VinFast Auto Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) shares are slightly lower on Thursday following the company&#8217;s announcement of strong<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener"> fourth-quarter 2024 vehicle deliveries.</a>
In an exchange <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1913510/000110465925012552/tm256507d1_ex99-1.htm" rel="noreferrer noopener">filing</a>, VinFast said it delivered 53,139 electric vehicles globally in the fourth quarter, marking a 143% quarter-over-quarter increase and a 342% year-over-year rise.
This performance helped the company achieve a record 97,399 EVs delivered globally for the full year 2024, exceeding its revised guidance of 80,000 vehicles, and representing a 192% year-over-year increase.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/25/01/43078297/teslas-vietnamese-rival-vinfast-enters-indias-ev-market-amid-global-expansion-push-plans-500-million-investment" rel="noreferrer noopener">Tesla&#8217;s Vietnamese Rival VinFast Enters &#8216;Next Growth Frontier&#8217; India Amid Global Expansion Push, Plans $500 Million Investment</a>
Driven by strong demand for affordable models and domestic market in Vietnam, VinFast achieved new delivery records for three consecutive months during the quarter under review.
Building on this momentum, the company is targeting to at least double its global deliveries in 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43702926/coinbase-stock-soars-108-in-a-year-heres-what-charts-say-before-q4-earnings" rel="noreferrer noopener">Coinbase Stock Soars 108% In A Year – Here&#8217;s What Charts Say Before Q4 Earnings</a>
In January 2025, VinFast&#8217;s domestic deliveries reached over 10,000, including more than 4,000 VF 3s and 3,300 VF 5s.
Additionally, the company delivered 31,170 e-scooters and e-bikes in the fourth quarter, a 65% increase from the previous quarter.
For the full year 2024, e-scooter and e-bike deliveries totaled 70,977, a 1% increase year-over-year.
VinFast said it plans to release its fourth quarter and full-year 2024 financial results on April 24.
Price Action: VFS shares are trading lower by 0.807% to $3.72 at last check Thursday. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43686908/us-stocks-set-for-a-mixed-start-following-higher-inflation-print-expert-says-earnings-remain-strong-despite-uncertainty" target="_blank" rel="noreferrer noopener">US Stocks Set For A Mixed Start Following Higher Inflation Print: Expert Says Earnings Remain Strong Despite Uncertainty</a></li>
</ul>
Image Via Shutterstock.

Equities

Markets

Tesla's Vietnamese Rival VinFast's Explosive Growth: 342% Surge In Q4 EV Deliveries Amid Ambitious 2025 Goals

BMO Capital analyst John McNulty maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Outperform and raises the price target from $105 to $112.

BMO Capital Maintains Outperform on DuPont de Nemours, Raises Price Target to $112

BMO Capital analyst Keith Bachman maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Outperform and raises the price target from $690 to $885.

HUBS

BMO Capital Maintains Outperform on HubSpot, Raises Price Target to $885

Walker & Dunlop shares are trading lower. The company reported Q4 financial results.

BMO Capital analyst Jeffrey Silber maintains S&amp;P Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGI#NYSE">SPGI</a>) with a Outperform and raises the price target from $576 to $590.

SPGI

BMO Capital Maintains Outperform on S&P Global, Raises Price Target to $590

<a href="https://www.betaville.co.uk/betaville-intelligence/zzw3nfk5yt6r8ong86z2towxd0jf9gj578lk" title="https://www.betaville.co.uk/betaville-intelligence/zzw3nfk5yt6r8ong86z2towxd0jf9gj578lk">https://www.betaville.co.uk/betaville-intelligence/zzw3nfk5yt6r8ong86z2towxd0jf9gj578lk</a>

RIOT

Watching Riot Platforms; Shares See Volume, Traders Circulate 'Uncooked Alert' From Betaville

BMO Capital analyst Evan Seigerman maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Market Perform and lowers the price target from $156 to $139.

BIIB

BMO Capital Maintains Market Perform on Biogen, Lowers Price Target to $139

Macquarie analyst Chad Beynon maintains MGM Resorts Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) with a Outperform and maintains $50 price target.

Macquarie Maintains Outperform on MGM Resorts Intl, Maintains $50 Price Target

Rapid7 shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results and issued Q1 and FY25 guidance below estimates. Also, multiple firms lowered their respective price targets on the stock.

On Thursday, Agios Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to &lt;18 years with PK deficiency who are not regularly transfused achieved its primary <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43687696/agios-phase-3-activate-kids-study-of-mitapivat-in-children-with-pyruvate-kinase-pk-deficiency-not-" rel="noreferrer noopener">endpoint of hemoglobin response</a>.
Pyruvate kinase (PK) deficiency is&nbsp;a rare, inherited disorder that affects red blood cells.
The safety results were consistent with the safety profile for mitapivat previously observed for adult patients with PK deficiency who are not regularly transfused.
The study&#8217;s primary endpoint was hemoglobin response, defined as a ≥1.5 g/dL ​increase in hemoglobin concentration from baseline ​ sustained at two or more scheduled assessments at​ Weeks 12, 16, and 20.
<ul>
<li>In addition, the pre-specified supportive analysis based on traditional methodology comparing the hemoglobin response rate for mitapivat versus placebo provided further evidence that the primary endpoint was met.</li>
<li>31.6% (6/19) of patients in the mitapivat arm achieved a hemoglobin response compared to 0% (0/11) of patients in the placebo arm; the 95% confidence interval for the difference in hemoglobin response rates between mitapivat and placebo was >0 (95% CI=10.8% to 52.7%). </li>
<li>In addition, improvements in changes from baseline for markers of hemolysis (indirect bilirubin, lactate dehydrogenase and haptoglobin) were observed in the mitapivat arm compared to the placebo arm.</li>
</ul>
In August 2024, Agios reported topline results from the&nbsp;ACTIVATE-KidsT Phase 3 study&nbsp;of mitapivat in children aged 1 to &lt;18 years with PK deficiency <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40110159/agios-pharmaceuticals-rare-blood-disorder-drug-misses-primary-goal-in-pediatric-study-stock-slide" rel="noreferrer noopener">who are regularly transfused</a>.
<ul>
<li>In the ACTIVATE-KidsT study, 28.1% of patients in the mitapivat arm achieved the primary endpoint of transfusion reduction response, compared to 11.8% of patients in the placebo arm.</li>
<li>Transfusion-free and normal hemoglobin response were secondary endpoints in this study and were only observed in patients in the mitapivat arm.</li>
</ul>
Based on the clinically meaningful results observed in both the ACTIVATE-Kids and ACTIVATE-KidsT Phase 3 studies, Agios intends to submit a marketing application for mitapivat in pediatric patients with PK deficiency.
Concurrently, the company reported fourth-quarter Pyrukynd&nbsp;revenues of $10.7 million, up 20% sequentially, beating the consensus of $9.33 million. 223 unique patients have completed prescription enrollment forms, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43687726/agios-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-business-highlights" rel="noreferrer noopener">up 6% sequentially</a>.
A total of 130 patients are on PYRUKYND therapy, inclusive of new prescriptions and continued therapy.
Cash, cash equivalents, and marketable securities as of December 31, 2024, were $1.5 billion.
Price Action: AGIO stock is down 1.86% at $32.20 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43691982/iron-mountain-q4-earnings-storage-and-data-center-revenue-growth-dividend-climbs-10-strong-2025-outlook" target="_blank" rel="noreferrer noopener">Iron Mountain Q4 Earnings: Storage And Data Center Revenue Growth, Dividend Climbs 10%, Strong 2025 Outlook</a></li>
</ul>

Biotech

AGIO

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

Herc Holdings shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results.

Investors with a lot of money to spend have taken a bullish stance on IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IONQ, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for IonQ.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 26%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $299,576, and 9 are calls, for a total amount of $665,523.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $10.0 to $50.0 for IonQ over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in IonQ's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to IonQ's substantial trades, within a strike price spectrum from $10.0 to $50.0 over the preceding 30 days.
<h3>IonQ Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739468732_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$14.75</td>
<td>$14.5</td>
<td>$14.5</td>
<td>$40.00</td>
<td>$290.0K</td>
<td>1.7K</td>
<td>408</td>
</tr>
<tr>
<td>IONQ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$3.85</td>
<td>$3.8</td>
<td>$3.85</td>
<td>$25.00</td>
<td>$84.3K</td>
<td>2.4K</td>
<td>234</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$25.15</td>
<td>$23.0</td>
<td>$24.75</td>
<td>$20.00</td>
<td>$74.2K</td>
<td>1.7K</td>
<td>41</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$9.05</td>
<td>$8.7</td>
<td>$8.7</td>
<td>$50.00</td>
<td>$69.6K</td>
<td>930</td>
<td>101</td>
</tr>
<tr>
<td>IONQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/14/25</td>
<td>$0.5</td>
<td>$0.47</td>
<td>$0.5</td>
<td>$39.50</td>
<td>$48.2K</td>
<td>542</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About IonQ</h3>
IonQ Inc sells access to several quantum computers of various qubit capacities and is in the process of researching and developing technologies for quantum computers with increasing computational capabilities. The company currently makes access to its quantum computers available via cloud platforms and also to select customers via its own cloud service. This cloud-based approach enables the broad availability of quantum-computing-as-a-service (QCaaS). The company derives its revenue from its quantum-computing-as-a-service arrangements, consulting services related to co-developing algorithms on company's quantum computing systems, and contracts associated with the design, development, and construction of specialized quantum computing systems together with related services.
In light of the recent options history for IonQ, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is IonQ Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 8,844,755, with IONQ's price down by -1.54%, positioned at $37.41.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for IonQ, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

IONQ

Decoding IonQ's Options Activity: What's the Big Picture?

BMO Capital analyst Ari Klein maintains Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) with a Outperform and lowers the price target from $1085 to $1065.

EQIX

BMO Capital Maintains Outperform on Equinix, Lowers Price Target to $1065

Whales with a lot of money to spend have taken a noticeably bearish stance on Starbucks.
Looking at options history for Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) we detected 27 trades.
If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened trades with bullish expectations and 51% with bearish.
From the overall spotted trades, 7 are puts, for a total amount of $336,756 and 20, calls, for a total amount of $80,960,705.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $75.0 and $125.0 for Starbucks, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Starbucks stands at 3351.79, with a total volume reaching 77,583.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Starbucks, situated within the strike price corridor from $75.0 to $125.0, throughout the last 30 days.
<h3>Starbucks Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739468727_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$43.35</td>
<td>$41.2</td>
<td>$41.5</td>
<td>$75.00</td>
<td>$12.4M</td>
<td>21.8K</td>
<td>16.0K</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$43.7</td>
<td>$41.5</td>
<td>$41.5</td>
<td>$75.00</td>
<td>$12.4M</td>
<td>21.8K</td>
<td>10.0K</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$43.65</td>
<td>$41.2</td>
<td>$41.2</td>
<td>$75.00</td>
<td>$12.3M</td>
<td>21.8K</td>
<td>16.0K</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/18/26</td>
<td>$43.7</td>
<td>$41.0</td>
<td>$41.2</td>
<td>$75.00</td>
<td>$9.3M</td>
<td>21.8K</td>
<td>21.2K</td>
</tr>
<tr>
<td>SBUX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$43.8</td>
<td>$40.05</td>
<td>$41.8</td>
<td>$75.00</td>
<td>$4.1M</td>
<td>21.8K</td>
<td>2.0K</td>
</tr>
</tbody>
</table>

<h3>About Starbucks</h3>
Starbucks is one of the most widely recognized restaurant brands in the world, operating more than 40,000 stores across more than 80 countries as of the end of fiscal 2024. The firm operates in three segments: North America, international markets, and channel development (grocery and ready-to-drink beverage). The coffee chain generates revenue from company-operated stores, royalties, sales of equipment and products to license partners, ready-to-drink beverages, packaged coffee sales, and single-serve products.
Having examined the options trading patterns of Starbucks, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Starbucks</h3>
<ul>
<li>Currently trading with a volume of 3,792,529, the SBUX's price is up by 0.01%, now at $113.05. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 75 days.</li>
</ul>
<h3>Expert Opinions on Starbucks</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $113.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Starbucks, which currently sits at a price target of $114. 
&#x2A; An analyst from RBC Capital downgraded its action to Outperform with a price target of $115. 
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Starbucks, targeting a price of $115. 
&#x2A; Maintaining their stance, an analyst from Wedbush continues to hold a Neutral rating for Starbucks, targeting a price of $100. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Starbucks, which currently sits at a price target of $124. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Starbucks, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

SBUX

Starbucks's Options: A Look at What the Big Money is Thinking

Whales with a lot of money to spend have taken a noticeably bullish stance on Lockheed Martin.
Looking at options history for Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish expectations and 22% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $86,829 and 7, calls, for a total amount of $370,855.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $230.0 to $510.0 for Lockheed Martin during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Lockheed Martin's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Lockheed Martin's substantial trades, within a strike price spectrum from $230.0 to $510.0 over the preceding 30 days.
<h3>Lockheed Martin Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739468722_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$155.2</td>
<td>$153.9</td>
<td>$153.97</td>
<td>$300.00</td>
<td>$76.9K</td>
<td align="right">38</td>
<td align="right">5</td>
</tr>
<tr>
<td>LMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$67.4</td>
<td>$65.3</td>
<td>$66.35</td>
<td>$400.00</td>
<td>$66.3K</td>
<td align="right">93</td>
<td align="right">11</td>
</tr>
<tr>
<td>LMT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$7.7</td>
<td>$7.5</td>
<td>$7.5</td>
<td>$430.00</td>
<td>$59.2K</td>
<td align="right">766</td>
<td align="right">88</td>
</tr>
<tr>
<td>LMT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$20.0</td>
<td>$18.5</td>
<td>$18.5</td>
<td>$500.00</td>
<td>$55.5K</td>
<td align="right">396</td>
<td align="right">39</td>
</tr>
<tr>
<td>LMT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$10.0</td>
<td>$9.8</td>
<td>$10.0</td>
<td>$505.00</td>
<td>$49.0K</td>
<td align="right">5</td>
<td align="right">54</td>
</tr>
</tbody>
</table>

<h3>About Lockheed Martin</h3>
Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Aeronautics is Lockheed's largest segment, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, mainly encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.
After a thorough review of the options trading surrounding Lockheed Martin, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Lockheed Martin</h3>
<ul>
<li>Currently trading with a volume of 550,162, the LMT's price is up by 0.44%, now at $443.92. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 68 days.</li>
</ul>
<h3>What The Experts Say On Lockheed Martin</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $541.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Lockheed Martin, which currently sits at a price target of $535. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Lockheed Martin, maintaining a target price of $540. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Lockheed Martin, maintaining a target price of $525. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Lockheed Martin, targeting a price of $600. 
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Lockheed Martin, which currently sits at a price target of $508. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Lockheed Martin, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Lockheed Martin's Options: A Look at What the Big Money is Thinking

Learn About Cryptocurrency

acf/sidebar-related-posts

Learn about this leading blockchain platform that supports decentralized applications and smart contracts.

What is Ethereum?

Earning interest on your Ethereum is a great way to grow your cryptocurrency holdings. Find out how to earn interest on your Ethereum in 4 easy steps.

How to Earn Interest on Ethereum

Discover the 10 best cryptocurrencies to invest in for January 2025. Stay ahead in the crypto market with our expert insights and analysis! Learn more now!

10 Best Cryptocurrencies to Invest In for February 2025

10 Best Cryptocurrencies to Invest in for January 2025

Discover the best altcoins to invest in for high potential returns. Our top altcoin picks include Ethereum, Solana, Ripple, Dogecoin, Toncoin.

Top 10 Best Altcoins • Benzinga Crypto

10 Best Altcoins in November 2024

Top Cryptocurrency News

acf/news-feed

Aperto	-
Chiuso	-
Volume / Media	5.86K / 4.83K
Intervallo giornaliero	- - -
Intervallo a 52 settimane	24.58 - 26.50
Capitalizzazione di mercato	-
Rapporto P/E	-
Rendimento del dividendo	10.43%
Exchange	NYSE
RSI	0
Vendite allo scoperto	-
Periodo di copertura	-

Aperto	-
Chiuso	-
Volume / Media	5.86K / 4.83K
Intervallo giornaliero	- - -
Intervallo a 52 settimane	24.58 - 26.50
Capitalizzazione di mercato	-
Rapporto P/E	-
Rendimento del dividendo	10.43%
Exchange	NYSE
RSI	0
Vendite allo scoperto	-
Periodo di copertura	-

Comments

GasLog Partners

GasLog Partners (GLOPpC) Previsione

GasLog Partners (NYSE:GLOPpC) Azioni Citazioni e riassunti delle notizie

Notizie recenti

Dati finanziari

Confronta

FAQ

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Nome

Ricavi Variazioni
Lordo Variazioni
EBITDA Variazioni
EBIT Variazioni
Utili Variazioni